Fig. 7
A CXCR2 antagonist inhibits tumor progression by Snail. a Tumor growth in mice subcutaneously injected with HM-1-control cells or HM-1-shSnail cells, treated with anti-Ly6G antibody (400 µg/body) or IgG twice a week from day 1 after tumor inoculation. P-values represent significance between two groups at day 19; n = 5–6. b Flow cytometric analyses of subcutaneous HM-1-control tumors treated with anti-Ly6G antibody or IgG at day 19. Percentage of positive cells relative to total cells is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n = 6. c Flow cytometric analyses of subcutaneous HM-1-shSnail tumors treated with anti-Ly6G antibody or IgG at day 19. The percentage of positive cells relative to total cell count is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n = 5–6. d Tumor growth in mice subcutaneously injected with HM-1-control cells or HM-1-shSnail cells, treated with SB265610 (2 mg/kg body weight) or PBS six times a week from day 1 after tumor inoculation. P-values represent significance between two groups at day 21; n = 4–6. e Flow cytometric analyses of subcutaneous HM-1-control tumors treated with SB265610 or PBS at day 21. Percentage of positive cells relative to total cells is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n = 5-6. f Flow cytometric analyses of subcutaneous HM-1-shSnail tumors treated with SB265610 or PBS at day 21. The percentage of positive cells relative to total cell count is plotted. MDSCs (left) and CD8+T cells/MDSCs (right); n = 4–5. *P < 0.05, **P < 0.01 and, ***P < 0.001 (unpaired t-test in a–f)
